12 completed, 5 terminated, 2 recruiting, 1 active not recruiting. 23 Phase 2, 3 Phase 1, 3 Phase 3.
Follow Pemphigus: new trials by email Literature Review of Pemphigus trials Research Report on Pemphigus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313. CM313 (SC), Glucocorticoids - Pemphigus Disease, Pemphigus Vulgaris (PV) | Phase 1 / Phase 2 | Not yet recruiting | Chao Ji | 100 | 2025-10-01 | 2024-10-29 |
| A Clinical Study of B007 in the Treatment of Pemphigus. B007 - Pemphigus | Phase 2 / Phase 3 | Recruiting | Shanghai Jiaolian Drug Research and Development Co., Ltd | 132 | 2024-07-12 | 2026-05-05 |
| Effect of Topical Insulin on Healing Rate of Pemphigus Lesions insulin glargine, human insulin, 0.9% Normal Saline - Pemphigus Vulgaris, Skin Erosion | Phase 2 | Completed | Alexandria University | 20 | 2024-06-22 | 2026-03-10 |
| COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders Moderna mRNA-1273, BNT162b2, Ad26.COV2.S - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 258 | 2021-08-13 | 2026-06-10 |
| Dexamethasone Solution and Dexamethasone in Mucolox™ dexamethasone 0.5mg/5ml solution, dexamethasone 0.5mg/5ml solution in Mucolox™ - Oral Lichen Planus, Mucous Membrane Pemphigoid | Phase 2 | Completed | University of California, San Francisco | 29 | 2020-12-26 | 2023-12-15 |
| A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) DSG3-CAART, CABA-201 - Pemphigus Vulgaris | Phase 1 / Phase 2 | Recruiting | Cabaletta Bio | 40 | 2020-09-29 | 2026-10-15 |
| IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus Rituximab, IVIg - Pemphigus | Phase 2 | Active not recruiting | The University of Hong Kong | 20 | 2020-06-20 | 2025-07-08 |
| Efficacy of Interleukin-2 Gargle in the Treatment of Oral Mucosa Lesion in Pemphigus Vulgaris recombinant human interleukin-2 (rhIL-2), placebo - Pemphigus Vulgaris | Phase 2 | Unknown | Second Xiangya Hospital of Central South University | 180 | 2020-04-02 | 2021-02-02 |
| A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris Parsaclisib - Pemphigus Vulgaris | Phase 2 | Withdrawn | Incyte Corporation | 2019-03-01 | 2019-09-13 | |
| A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus ARGX-113 - Pemphigus Vulgaris, Pemphigus Foliaceus | Phase 2 | Completed | argenx | 34 | 2017-10-18 | 2020-12-14 |
| A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) ALXN1830 - Pemphigus, Pemphigus Vulgaris | Phase 1 / Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 8 | 2017-07-18 | 2020-02-05 |
| A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris PRN1008 - Pemphigus Vulgaris | Phase 2 | Completed | Principia Biopharma, a Sanofi Company | 42 | 2016-01-22 | 2023-02-13 |
| Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris VAY736, Placebo - Pemphigus Vulgaris | Phase 2 | Terminated | Novartis Pharmaceuticals | 13 | 2013-12-18 | 2021-10-08 |
| Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine - Pemphigus | Phase 2 | Completed | University of Luebeck | 23 | 2008-01-01 | 2017-03-13 |
| Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone Azathioprine, Prednisone, Placebo - Pemphigus Vulgaris | Phase 2 | Completed | Tehran University of Medical Sciences | 48 | 2008-01-01 | 2010-11-30 |
| Use of KC706 for the Treatment of Pemphigus Vulgaris KC706 - Pemphigus Vulgaris | Phase 2 | Completed | Kemia, Inc | 20 | 2007-11-01 | 2008-06-19 |
| Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus intravenous immunoglobulin, cyclophosphamide - Pemphigus Vulgaris | Phase 2 | Terminated | NYU Langone Health | 9 | 2007-04-01 | 2016-02-18 |
| Use of Infliximab for the Treatment of Pemphigus Vulgaris Infliximab, Placebo Comparator - Pemphigus | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2006-03-01 | 2017-12-06 |
| Study of Etanercept (Enbrel) in the Treatment of Pemphigus Vulgaris Enbrel (Etanercept) - Pemphigus Vulgaris | Phase 2 | Completed | Massachusetts General Hospital | 12 | 2004-06-01 | 2015-06-03 |
| Effect of Anti CD20 in Pemphigus Desease Mabthera - Pemphigus | Phase 2 / Phase 3 | Completed | University Hospital, Rouen | 22 | 2003-06-01 | 2013-06-18 |
Showing 20 of 23. Sign in to see all of them.
Autoimmune Diseases (3) · Immune System Diseases (2) · Arthritis, Juvenile (1) · Arthritis, Rheumatoid (1) · Bronchiolitis Obliterans Syndrome (1) · COVID-19 (1) · Communicable Diseases (1) · Dermatomyositis (1) · Insulin Resistance (1) · Lichen Planus, Oral (1) · Lupus Erythematosus, Systemic (1) · Multiple Sclerosis (1) · Pemphigoid, Benign Mucous Membrane (1) · Rare Diseases (1)
Skin and Connective Tissue Diseases (23) · Skin Diseases (22) · Skin Diseases, Vesiculobullous (22) · Immune System Diseases (21) · Autoimmune Diseases (20) · Infections (2) · Lung Diseases (2) · Respiratory Tract Diseases (2) · Arthritis (1) · Autoimmune Diseases of the Nervous System (1) · Bronchial Diseases (1) · Bronchiolitis (1) · Bronchiolitis Obliterans (1) · Bronchitis (1) · Conjunctival Diseases (1)
Dexamethasone (3) · Rituximab (3) · Azathioprine (2) · Cyclophosphamide (2) · Immunoglobulins, Intravenous (2) · 2019-nCoV Vaccine mRNA-1273 (1) · Ad26COVS1 (1) · BNT162 Vaccine (1) · BNT162b5 (1) · COVID-19 Vaccines (1) · Dapsone (1) · Etanercept (1) · Filgrastim (1) · Glucocorticoids (1) · Infliximab (1)
National Institute of Allergy and Infectious Diseases (NIAID) (2) · Alexandria University (1) · Alexion Pharmaceuticals, Inc. (1) · Cabaletta Bio (1) · Chao Ji (1) · Incyte Corporation (1) · Jacobus Pharmaceutical (1) · Johns Hopkins University (1) · Kemia, Inc (1) · Massachusetts General Hospital (1) · NYU Langone Health (1) · Novartis Pharmaceuticals (1) · Principia Biopharma, a Sanofi Company (1) · Second Xiangya Hospital of Central South University (1) · Shanghai Jiaolian Drug Research and Development Co., Ltd (1)
United States (11) · China (2) · France (2) · Germany (2) · Israel (2) · Australia (1) · Austria (1) · Bulgaria (1) · Croatia (1) · Egypt (1) · Greece (1) · Hong Kong (1) · Hungary (1) · Iran (1) · Italy (1)
Amit Pandya, MD (2) · Neil Korman, MD (2) · Victoria Werth, MD (2) · Alessandro Villa, DDS, PhD, MPH (1) · Alexandra B Kimball, MD, MPH (1) · Amit Bar-Or, MD, FRCP (1) · Bruce Strober, MD (1) · Cabaletta Bio (1) · Carmen I Farid, MB BCh, MD (1) · Cheyda Chams-Davatchi, MD (1) · David Rubenstein, MD, PhD (1) · David Woodley, MD (1) · Detlef Zillikens, MD (1) · Diana Chen, MD (1)
PMID 16702494, PMID 17687130, PMID 18209165, PMID 25123295, PMID 34126109, PMID 34608631, PMID 35663943, PMID 37549933, PMID 38608709, PMID 41289027, PMID 42201777
2015 (1), 2017 (1)